TICKERNERD
Menu
PENPENHealthcare · Medical Devices

PEN Stock Forecast: Penumbra, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$320
+0.03% on the day

The 17 Wall Street analysts covering Penumbra, Inc. hold a median 12-month price target of $374 — +16.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 14 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$12.6B
Ticker Nerd rank
77 / 100
Median analyst target
$374
Analysts covering
17
Revenue$390.0M+14.9% y/y
Operating income$41.0M
Net income$34.8M
Free cash flow$32.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.2%
1M
+0.1%
YTD
+3.0%
1Y
+25.6%
From 52W high
−10.9%
From 52W low
+41.9%
$226
$359
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Penumbra, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
97
Quality
95
Momentum
82
Issuance
69
Value
65
Growth
57
Accruals
56
Revisions
53
Size
13

Volatility (97): The share price has been relatively steady.

Revisions (53): Analysts have, on balance, been cutting their forecasts.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Jan 26Apr 26Jul 26Oct 26PENHigh $374Median $374Low $320

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
3 Buy14 Hold0 Sell
Low $320Median $374High $374

The green dot is the last close — the median target sits +16.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026Evercore ISI GroupMaintainsOutperform$335 → $320
11 June 2026RBC CapitalReiteratesSector Perform—
7 May 2026CitigroupMaintainsNeutral—
7 May 2026Evercore ISI GroupMaintainsOutperform—
26 Feb 2026Evercore ISI GroupMaintainsOutperform—
20 Jan 2026Canaccord GenuityDowngradeHold—
20 Jan 2026RBC CapitalDowngradeSector Perform—
16 Jan 2026BairdDowngradeNeutral—
16 Jan 2026BTIGDowngradeNeutral—
16 Jan 2026CitigroupDowngradeNeutral—
16 Jan 2026JefferiesDowngradeHold—
16 Jan 2026Leerink PartnersDowngradeMarket Perform—
16 Jan 2026NeedhamDowngradeHold—
16 Jan 2026Truist SecuritiesDowngradeHold—
15 Jan 2026Wells FargoDowngradeEqual-Weight—
15 Jan 2026William BlairDowngradeMarket Perform—
5 Jan 2026B of A SecuritiesMaintainsBuy—
18 Dec 2025JP MorganUpgradeOverweight—
18 Dec 2025Truist SecuritiesMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Penumbra, Inc. returned +25.6% against +17.5% for the S&P 500, dividends included.

PEN vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26PENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.8%
Analysts raising
1
Analysts cutting
5
Fundamentals

Penumbra, Inc. (PEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
78.6×

Cheaper than 9% of US stocks

Price / sales
8.4×

Cheaper than 16% of US stocks

Price / book
8.2×

Cheaper than 11% of US stocks

EV / EBITDA
59.7×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
14.9%

Higher than 62% of US stocks

Earnings growth (YoY)
−23.1%

Higher than 19% of US stocks

Gross margin
67.9%

Higher than 81% of US stocks

Operating margin
10.5%

Higher than 65% of US stocks

Net margin
10.7%

Higher than 71% of US stocks

Returns & dividend
Return on equity
11.4%

Higher than 67% of US stocks

Return on assets
6.4%

Higher than 83% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Penumbra, Inc. (PEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Penumbra, Inc. has a market value of $12.6B and an enterprise value of $12.2B.

  • Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 14.9% year on year.

  • Net income over the same four quarters: $160.6M, a 10.7% net margin.

  • Diluted earnings per share, trailing twelve months: $4.07.

  • Free cash flow in the twelve months to 30 June 2026: $215.9M.

  • Shares outstanding: 39.4M.

  • Trailing P/E: 78.6×; forward P/E: 52.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Penumbra, Inc. employs 4,700 people — $320K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

PEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PENPenumbra, Inc.$12.6B
77
GMEDGlobus Medical, Inc.$10.2B
96
GKOSGlaukos Corp.$9.9B
88
BIOBio-Rad Laboratories, Inc.$9.7B
91
TXG10X Genomics, Inc.$9.5B
94
PODDInsulet Corp.$9.3B
90
ZBHZimmer Biomet Holdings, Inc.$18.2B
91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Penumbra, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PEN news & analysis

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

PRNewsWire · 6 Oct 2026positive

Penumbra announced a subset analysis of the STORM-PE randomized controlled trial, reporting a significant correlation between wearable-tracked daily step activity and performance on the clinical 6-minute walk test in patients with pulmonary embolism.

Why it matters — The findings offer evidence about how wearable activity data may reflect real-world functional recovery among patients treated with CAVT and anticoagulation or anticoagulation alone.

IART vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research · 1 Oct 2026neutral

Zacks Investment Research published an article comparing Integra LifeSciences (IART) and Penumbra (PEN), both in the Medical - Instruments sector, to assess which stock currently offers better value for value investors.

Why it matters — Penumbra watchers would care because the piece evaluates PEN's relative value positioning against a sector peer, informing how the stock is viewed by value-oriented investors.

IART or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 29 Sept 2026neutral

Zacks Investment Research published a comparison of Integra LifeSciences (IART) and Penumbra (PEN) in the Medical - Instruments sector, examining which of the two companies offers the better value for investors seeking undervalued stocks. The article evaluates the two companies side by side on value metrics.

Why it matters — PEN watchers would care because the piece positions Penumbra in a value-stock comparison against a peer, which could influence how investors assess its attractiveness.

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Zacks Investment Research · 16 Sept 2026neutral

Zacks Investment Research published a note advising investors to retain their Penumbra (PEN) shares for now, citing portfolio expansion and international growth as supporting momentum, while identifying rising costs, foreign exchange exposure, and margin pressure as key risks.

Why it matters — A PEN watcher would care because the analysis frames the company's growth drivers against the margin and foreign-exchange pressures that could shape its near-term performance.

TFX vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research · 11 Sept 2026neutral

Zacks Investment Research published a comparison piece examining Teleflex (TFX) and Penumbra (PEN), both in the Medical - Instruments segment, to determine which is the more attractive option for value investors.

Why it matters — A PEN watcher would care because the article positions Penumbra for a value-oriented evaluation against a peer, potentially influencing how investors assess the stock.

FAQ

Frequently asked questions about PEN stock

What is the PEN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Penumbra, Inc. have a median 12-month price target of $374, with estimates ranging from $320 to $374. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PEN stock a buy right now?

Of the 17 analysts covering Penumbra, Inc., 3 rate it a Buy, 14 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Penumbra, Inc. 77 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PEN?

As at 14 Oct 2026, Penumbra, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).

Will PEN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +16.8% from the last close, and Ticker Nerd's factor model ranks Penumbra, Inc. 77 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PEN stock forecast for 2030?

No analyst covering Penumbra, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $320 to $374 over the next 12 months.

How has PEN stock performed over the past year?

Penumbra, Inc. returned +25.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Penumbra, Inc. do?

Penumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care.

What is the latest news on PEN?

The most recent item we track (PRNewsWire, 6 Oct 2026): "New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism". Penumbra announced a subset analysis of the STORM-PE randomized controlled trial, reporting a significant correlation between wearable-tracked daily step activity and performance on the clinical 6-minute walk test in patients with pulmonary embolism.

Company

About Penumbra, Inc.

Penumbra Inc. is a medical device company that designs, develops, manufactures, and markets products for interventional therapies in vascular and neurological care. Its portfolio centers on thrombectomy systems used to remove blood clots, including solutions for peripheral and neurovascular applications, along with access devices, embolization technologies, and neurosurgical tools. The company’s products are used in acute care settings by hospitals and physicians to support treatment of conditions such as stroke, pulmonary embolism, deep vein thrombosis, aneurysms, and other vascular disorders. Penumbra Inc. serves healthcare providers in the United States and international markets, positioning itself as a specialist in minimally invasive devices for complex clot-removal and vascular intervention procedures. Founded in 2004 and headquartered in Alameda, California, Penumbra Inc. focuses on medical technologies that address critical and time-sensitive clinical needs.

CEO Mr. Adam Elsesser J.D. · 4,700 employees · United States · https://www.penumbrainc.com